Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR T Cell Immunotherapy for Desensitization in Kidney Transplant Candidates
NCT06056102Phase 1Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2024
- Primary completion
- Dec 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CART-BCMA and huCART-19 in kidney failure (ESRD), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Timing of adverse events at 12 months, Frequency of adverse events at 12 months and 2 more. Started May 2024; status: recruiting.
02
Drugs
CART-BCMAhuCART-19
03
Conditions
kidney failure (ESRD)
Beyond the preview
Go deeper on NCT06056102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06056102.